Hormonal
Combination therapy with ARNIs and SGLT2 inhibitors produces synergistic cardiovascular, metabolic, and renal benefits in cardiometabolic syndrome (CMS) patients, though implementation is hindered by hypotension risks and cost.
If you have cardiometabolic syndrome, current guidelines suggest combining an ARNI (like sacubitril/valsartan) with an SGLT2 inhibitor (like empagliflozin or dapagliflozin) for the best heart, kidney, and metabolic protection. Start with low doses and increase slowly to avoid dizziness or low blood pressure. Monitor your kidney function and electrolytes regularly. Discuss insurance coverage with your provider, as these drugs can be expensive but are cost-effective long-term by preventing hospitalizations.
Combination therapy with ARNIs and SGLT2 inhibitors produces synergistic effects, further amplifying clinical benefits, although challenges such as hypotension, hyperkalemia, and cost remain.
Why this rating
Based on large-scale RCTs (PARADIGM-HF, DAPA-HF, EMPEROR) and post-hoc subgroup analyses, though CMS-specific dedicated trials are noted as lacking.
Source
Expanding the Role of Novel Therapeutics in Cardiometabolic Syndrome: Beyond Heart Failure and Diabetes
Hyun‐Jin Kim · CardioMetabolic Syndrome Journal · 2025
DOI 10.51789/cmsj.2025.5.e4
More from this paper
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.Strong
- Novel mineralocorticoid receptor antagonists (MRAs) like finerenone reduce cardiovascular events and slow CKD progression in CMS patients with lower hyperkalemia risk compared to traditional MRAs.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →